Berberine in Non-Alcoholic Fatty Liver Disease—A Review
Open Access
Abstract
The incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) has been rapidly increasing during the last decade. It is a relevant health problem that affects 25% of the general population. NAFLD involves an extensive array of clinical conditions. So far, no approved pharmacological therapy for NAFLD has been developed. Multiple bioactive compounds have been proposed to treat NAFLD. One of the most promising is Berberine (BBR). Its pleiotropic effect positively impacts various cardiometabolic aspects. In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy. BBR ameliorates NAFLD by affecting numerous abnormalities. It inhibits lipogenesis and gluconeogenesis, improves insulin resistance and lipid profile, and modulates gut microbiota. The exact mechanism underlying these effects is not yet entirely explained. A growing amount of evidence confirming the positive effects of BBR on multiple metabolic pathways, such as lipids and glucose metabolism, energy homeostasis, or gut microbiota modulation, allows us to speculate about the importance of this natural bioactive substance for NAFLD therapy.Keywords
Funding Information
- the large research grant from statutory funding for young researchers—doctoral students for 2022 (502-14-21191730-45058)
This publication has 60 references indexed in Scilit:
- Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2015
- Association between Noninvasive Fibrosis Markers and Cardio-Vascular Organ Damage among Adults with Hepatic SteatosisPLOS ONE, 2014
- Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profileLipids in Health and Disease, 2014
- Effect of Berberine Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin SecretionMetabolic Syndrome and Related Disorders, 2013
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseGastroenterology, 2013
- Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic controlDiabetes, Metabolic Syndrome and Obesity, 2012
- Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patientsAdvances in Therapy, 2011
- Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic GluconeogenesisPLOS ONE, 2011
- Berberine Regulated Gck, G6pc, Pck1 and Srebp-1c Expression and Activated AMP-activated Protein Kinase in Primary Rat HepatocytesInternational Journal of Biological Sciences, 2011
- Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statinsNature Medicine, 2004